Apollomics，LaunXP进入Vebreltinib的开发，商业协议

2025-03-31 21:20

Apollomics (NASDAQ:APLM) and LaunXP International, an affiliate of LaunXP Biomedical, announced that the parties have entered into an agreement for the development and commercialization in Asia of vebreltinib, Apollomics' proprietary c-Met inhibitor, in combination with an EGFR inhibitor or the treatment of NSCLC.
The EGFRi class of targeted kinase inhibitors is currently a foundational targeted therapy for the treatment of NSCLC and other tumor types.
Under the terms of the agreement, Apollomics is to receive upfront payments totaling $10M within 60 days of the date of the agreement.
Apollomics is also eligible for regulatory and other pre-commercial milestones up to $50M, and royalties on net product sales. LaunXP will be primarily responsible for the development of vebreltinib in combination with an EGFRi in the LaunXP territory for the treatment of NSCLC.
"We are delighted to partner with LaunXP, who share our vision for the commercial opportunity for vebreltinib. EGFRi is currently the frontline treatment for many patients with NSCLC, and combining it with our c-Met inhibitor vebreltinib is expected to transform the standard of care," said Dr. Guo-Liang Yu, CEO of Apollomics.
APLM +7.6% premarket to $7.61.

More on Apollomics